{"DataElement":{"publicId":"5985746","version":"1","preferredName":"Breast Cancer AJCC Edition 8 Clinical Prognostic Group Stage","preferredDefinition":"Clinical stage group for breast carcinoma based on the combined evaluation of T, N, and M categories that should be used in countries where HER2, ER, and PR biomarker tests are routinely performed for patient care (US, Canada, etc.), using AJCC Ed. 8 criteria.","longName":"BRST_AJC8_CLN_STG","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"3671773","version":"1","preferredName":"Breast Tumor Clinical Stage Grouping","preferredDefinition":"information related to the assessment of a neoplasm of the breast based on the combined evaluation of the patient's T stage, M stage, and N stage. (caDSR)_Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage.","longName":"2206465v1.0:2925061v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2206465","version":"1","preferredName":"Breast Neoplasm","preferredDefinition":"One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.:(NEE-o-PLAY-zha) Abnormal and uncontrolled cell growth.","longName":"C12971:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast","conceptCode":"C12971","definition":"One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-F64A-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2925061","version":"1","preferredName":"Clinical Stage Grouping","preferredDefinition":"Having to do with the examination and treatment of patients.:Stage Grouping; an assessment based on the combined evaluation of the patient's T stage, M stage, and N stage. (caDSR)","longName":"C25398:C38027","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical","conceptCode":"C25398","definition":"Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FD8E36A-281E-6D78-E040-BB89AD43144A","latestVersionIndicator":"Yes","beginDate":"2009-07-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-07-29","modifiedBy":"ONEDATA","dateModified":"2009-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D488C938-7573-4778-E040-BB89AD4320D7","latestVersionIndicator":"Yes","beginDate":"2013-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-01-30","modifiedBy":"TAYLORT","dateModified":"2019-05-02","changeDescription":"Created for Caris CRF per request by B.Maeske. mc 1/30/13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6005742","version":"1","preferredName":"Breast Carcinoma American Joint Committee on Cancer Edition 8 Prognostic Group Stage","preferredDefinition":"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should be used in countries where HER2, ER, and PR biomarker tests are routinely performed for patient care (U.S., Canada, etc.). (from AJCC 8th Ed.)_An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers._The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"6005742v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"4","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"IV","valueDescription":"Prognostic Stage IV Breast Cancer AJCC v8","ValueMeaning":{"publicId":"6044635","version":"1","preferredName":"Prognostic Stage IV Breast Cancer AJCC v8","longName":"6044635","preferredDefinition":"Stage IV includes: Any T, Any N, M1, G1-3, HER2 Status: Any, ER Status: Any, PR Status: Any. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M1: Distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prognostic Stage IV Breast Cancer AJCC v8","conceptCode":"C139587","definition":"Stage IV includes: Any T, Any N, M1, G1-3, HER2 Status: Any, ER Status: Any, PR Status: Any. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M1: Distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"60B5C3B2-9719-56DF-E053-F662850ACB9E","latestVersionIndicator":"Yes","beginDate":"2017-12-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-12-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"71392A43-DB1B-58A0-E053-F662850A52C5","beginDate":"2018-07-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","deletedIndicator":"No"},{"value":"IIIC","valueDescription":"Prognostic Stage IIIC Breast Cancer AJCC v8","ValueMeaning":{"publicId":"6360495","version":"1","preferredName":"Prognostic Stage IIIC Breast Cancer AJCC v8","longName":"6360495","preferredDefinition":"Refer to NCIt C139585.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"71392A43-DB25-58A0-E053-F662850A52C5","latestVersionIndicator":"Yes","beginDate":"2018-07-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"71392A43-DB3E-58A0-E053-F662850A52C5","beginDate":"2018-07-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","deletedIndicator":"No"},{"value":"IIIB","valueDescription":"Prognostic Stage IIIB Breast Cancer AJCC v8","ValueMeaning":{"publicId":"6360496","version":"1","preferredName":"Prognostic Stage IIIB Breast Cancer AJCC v8","longName":"6360496","preferredDefinition":"Refer to NCIt C139584.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"71392A43-DB48-58A0-E053-F662850A52C5","latestVersionIndicator":"Yes","beginDate":"2018-07-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"71392A43-DB61-58A0-E053-F662850A52C5","beginDate":"2018-07-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","deletedIndicator":"No"},{"value":"0","valueDescription":"Prognostic Stage 0 Breast Cancer AJCC v8","ValueMeaning":{"publicId":"6044639","version":"1","preferredName":"Prognostic Stage 0 Breast Cancer AJCC v8","longName":"6044639","preferredDefinition":"Stage 0 includes: Tis, N0, M0, G1-3, HER2 Status: Any, ER Status: Any, PR Status: Any. Tis: Ductal carcinoma in situ. Lobular carcinoma in situ is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prognostic Stage 0 Breast Cancer AJCC v8","conceptCode":"C139555","definition":"Stage 0 includes: Tis, N0, M0, G1-3, HER2 Status: Any, ER Status: Any, PR Status: Any. Tis: Ductal carcinoma in situ. Lobular carcinoma in situ is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"60B5C3B2-9765-56DF-E053-F662850ACB9E","latestVersionIndicator":"Yes","beginDate":"2017-12-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-12-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7138E114-A057-5A31-E053-F662850A2487","beginDate":"2018-07-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","deletedIndicator":"No"},{"value":"IIA","valueDescription":"Prognostic Stage IIA Breast Cancer AJCC v8","ValueMeaning":{"publicId":"6360486","version":"1","preferredName":"Prognostic Stage IIA Breast Cancer AJCC v8","longName":"6360486","preferredDefinition":"Refer to NCIt C139571.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"71390B05-58BD-4042-E053-F662850AB31E","latestVersionIndicator":"Yes","beginDate":"2018-07-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"71390B05-58D6-4042-E053-F662850AB31E","beginDate":"2018-07-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","deletedIndicator":"No"},{"value":"IB","valueDescription":"Prognostic Stage IB Breast Cancer AJCC v8","ValueMeaning":{"publicId":"6360487","version":"1","preferredName":"Prognostic Stage IB Breast Cancer AJCC v8","longName":"6360487","preferredDefinition":"Refer to NCIt C139558.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"71390B05-58E0-4042-E053-F662850AB31E","latestVersionIndicator":"Yes","beginDate":"2018-07-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-17","modifiedBy":"TAYLORT","dateModified":"2018-07-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"71390B05-58F9-4042-E053-F662850AB31E","beginDate":"2018-07-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","deletedIndicator":"No"},{"value":"IA","valueDescription":"Prognostic Stage IA Breast Cancer AJCC v8","ValueMeaning":{"publicId":"6044637","version":"1","preferredName":"Prognostic Stage IA Breast Cancer AJCC v8","longName":"6044637","preferredDefinition":"Stage IA includes: (T1, N0, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T1, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (T0-1, N1mi, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T0-1, N1mi, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (MultiGene Panel-Oncotype Dx Recurrence Score Less Than 11, T1-2, N0, M0, G1-3, HER2 Status: Negative, ER Status: Positive, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prognostic Stage IA Breast Cancer AJCC v8","conceptCode":"C139557","definition":"Stage IA includes: (T1, N0, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T1, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (T0-1, N1mi, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T0-1, N1mi, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (MultiGene Panel-Oncotype Dx Recurrence Score Less Than 11, T1-2, N0, M0, G1-3, HER2 Status: Negative, ER Status: Positive, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"60B5C3B2-973F-56DF-E053-F662850ACB9E","latestVersionIndicator":"Yes","beginDate":"2017-12-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-12-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"71390B05-590D-4042-E053-F662850AB31E","beginDate":"2018-07-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","deletedIndicator":"No"},{"value":"IIIA","valueDescription":"Prognostic Stage IIIA Breast Cancer AJCC v8","ValueMeaning":{"publicId":"6360497","version":"1","preferredName":"Prognostic Stage IIIA Breast Cancer AJCC v8","longName":"6360497","preferredDefinition":"Refer to NCIt C139583.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"71392A43-DB6B-58A0-E053-F662850A52C5","latestVersionIndicator":"Yes","beginDate":"2018-07-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"71392A43-DB84-58A0-E053-F662850A52C5","beginDate":"2018-07-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","deletedIndicator":"No"},{"value":"IIB","valueDescription":"Prognostic Stage IIB Breast Cancer AJCC v8","ValueMeaning":{"publicId":"6360498","version":"1","preferredName":"Prognostic Stage IIB Breast Cancer AJCC v8","longName":"6360498","preferredDefinition":"Refer to NCIt C139572.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"71392A43-DB8E-58A0-E053-F662850A52C5","latestVersionIndicator":"Yes","beginDate":"2018-07-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"71392A43-DBA7-58A0-E053-F662850A52C5","beginDate":"2018-07-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-07-17","modifiedBy":"ONEDATA","dateModified":"2018-07-17","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6050750","version":"1","preferredName":"Breast Cancer by AJCC v8 Prognostic Stage Stage Grouping Stage","preferredDefinition":"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should be used in countries where HER2, ER, and PR biomarker tests are routinely performed for patient care (U.S., Canada, etc.). (from AJCC 8th Ed.):An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage.:The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"C139554:C38027:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Cancer by AJCC v8 Prognostic Stage","conceptCode":"C139554","definition":"A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should be used in countries where HER2, ER, and PR biomarker tests are routinely performed for patient care (U.S., Canada, etc.). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6271FDCB-9E88-31C3-E053-F662850A6F3A","latestVersionIndicator":"Yes","beginDate":"2018-01-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-01-10","modifiedBy":"ONEDATA","dateModified":"2018-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"5BEB7EA9-0DDF-4C27-E053-F662850A188D","latestVersionIndicator":"Yes","beginDate":"2017-10-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-19","modifiedBy":"TAYLORT","dateModified":"2019-05-03","changeDescription":"5-3-19 released; tmt. 7/17/18 edits to Draft New VD. 12/19/17 tt edits to Long Name. 11/17/17 tt edit to Long Name, associated with CS/CSI. 10/19/17 tt created for standardization; supercedes VD 3419357.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2180933","version":"1","longName":"FNL Research Activities","context":"CIP","ClassificationSchemeItems":[{"publicId":"6788757","version":"1","longName":"QIN Breast Study","context":"CIP"}]},{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6005920","version":"1","longName":"AJCC Edition 8","context":"NCI Standards"},{"publicId":"10000338","version":"1","longName":"Breast","context":"NCI Standards"}]}],"AlternateNames":[{"name":"Clinical Stage","type":"QIN Breast Study","context":"CIP"},{"name":"CIP","type":"USED_BY","context":"CIP"}],"ReferenceDocuments":[{"name":"Clinical disease stage","type":"Preferred Question Text","description":"Clinical disease stage","url":null,"context":"NCI Standards"},{"name":"ECOG-ACRIN - 1","type":"Alternate Question Text","description":"AJCC 8th Edition Clinical Stage","url":null,"context":"ECOG-ACRIN"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"5ABAF85A-A6CE-1AD8-E053-F662850A5F12","latestVersionIndicator":"Yes","beginDate":"2017-10-04","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-10-04","modifiedBy":"FINCHAMB","dateModified":"2023-02-10","changeDescription":"5-3-19 released; tmt. 5-2-19 edit to Draft New CDE/DEC; tmt.  7/18/18 edits to Draft New CDE.  12/19/17 tt associated with new DEC. 11/17/17 tt associated with CS/CSI, edit to Long and Short Name. 10/19/17 tt associated with new VD. 10/4/17  tt created for standardization. Incomplete pending updates to VD per NCIt Ed 8 caDSR concept loading; supercedes CDE 3419407.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}